In a 54‑year‑old woman with EGFR‑mutated non‑small cell lung cancer who progressed on adjuvant osimertinib with hepatic metastases, what is the role of amivantamab?

Amivantamab Plus Chemotherapy is a Strong Treatment Option After Osimertinib Progression

For this 54-year-old woman with EGFR-mutated NSCLC who progressed on adjuvant osimertinib with hepatic metastases, platinum-based chemotherapy (carboplatin-pemetrexed) combined with amivantamab should be offered as the preferred treatment approach. This recommendation is based on the most recent ASCO guidelines and robust phase III trial data demonstrating superior progression-free survival compared to chemotherapy alone 1, 2.

Evidence Supporting Amivantamab Plus Chemotherapy

The MARIPOSA-2 trial provides the strongest evidence for this approach 1, 3. In 657 patients who progressed on osimertinib, amivantamab plus carboplatin-pemetrexed demonstrated:

• Median PFS: 6.3 months vs 4.2 months with chemotherapy alone (HR 0.48, P<0.001)
• Objective response rate: 64% vs 36% with chemotherapy alone
• Intracranial PFS: 12.5 months vs 8.3 months, particularly relevant given the presence of metastatic disease

The 2024 ASCO guidelines provide a strong recommendation (moderate evidence quality) for offering platinum-based chemotherapy with or without amivantamab in this exact clinical scenario 1, 2.

Why This Regimen Over Alternatives

Superiority Over Chemotherapy Alone

The combination nearly doubles PFS compared to standard platinum-pemetrexed chemotherapy, with a clinically meaningful improvement in response rates 1. This is particularly important in a patient with hepatic metastases, where disease control is critical.

Advantage Over Immunotherapy

Anti-PD-(L)1 agents with or without chemotherapy are explicitly NOT recommended in this setting 1, 2. The CheckMate 722 and KEYNOTE-789 trials both failed to show PFS or OS benefit when adding immunotherapy to chemotherapy after EGFR TKI progression 1.

Mechanism of Action

Amivantamab is a bispecific antibody targeting both EGFR and MET, addressing common resistance mechanisms to osimertinib 4. It works through:

• Blocking ligand binding to EGFR and MET
• Receptor degradation
• Antibody-dependent cellular cytotoxicity (ADCC)
• Immune-mediated tumor cell destruction

Managing the Toxicity Profile

The main concern with amivantamab combinations is increased toxicity compared to chemotherapy alone 1:

Expected adverse events include:

• Hematologic toxicity (neutropenia, thrombocytopenia, anemia) - primarily chemotherapy-related
• EGFR-related: Rash (manageable grade 1-2), paronychia, stomatitis 5, 6
• MET-related: Peripheral edema
• Infusion-related reactions (13% with current formulations) 1

Key management strategies:

• Premedicate for infusion reactions per protocol
• Monitor blood counts closely during chemotherapy cycles
• Proactive skin care and nail care education
• Consider dose modifications for grade ≥3 toxicities

Real-world data confirms these toxicities are generally manageable, with most skin reactions being grade 1-2 6.

Special Consideration: Hepatic Metastases

While the patient has hepatic metastases, this should not preclude amivantamab use. Real-world evidence demonstrates efficacy even in patients with extensive visceral metastases, including dramatic responses in hepatic disease 5. The FDA label indicates no dose adjustment is needed for mild hepatic impairment 4.

Alternative if Amivantamab is Not Accessible

If amivantamab is unavailable or not tolerated, platinum-pemetrexed chemotherapy alone remains the standard of care 1, 7. Chemotherapy plus bevacizumab may be considered for adenocarcinoma histology if anti-VEGF therapy is deemed safe, though this patient's hepatic metastases warrant careful assessment of bleeding risk 1, 2.

What NOT to Do

• Do not use immunotherapy (pembrolizumab, nivolumab, atezolizumab) with or without chemotherapy - multiple phase III trials show no benefit 1
• Do not continue osimertinib - the disease has clearly progressed through this mechanism
• Do not delay treatment for additional molecular testing unless considering clinical trial enrollment

Monitoring and Next Steps

• Obtain baseline imaging including brain MRI given CNS tropism of EGFR-mutated disease
• Reassess response every 6-8 weeks with CT imaging
• Monitor for development of new targetable resistance mechanisms if progression occurs
• Consider tissue or liquid biopsy at progression to identify potential clinical trial opportunities

The combination of amivantamab with carboplatin-pemetrexed represents the most evidence-based approach for this patient, offering superior disease control compared to chemotherapy alone while avoiding ineffective immunotherapy strategies.